Technical Analysis for RUBY - Rubius Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 23.88 | -1.04% | -0.25 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Down |
| Historical RUBY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.04% | |
| Wide Bands | Range Expansion | -1.04% | |
| Oversold Stochastic | Weakness | -1.04% | |
| Fell Below 20 DMA | Bearish | 0.08% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 2% | 2 days ago |
| Down 1% | 2 days ago |
| Up 1% | 2 days ago |
Get a Trading Assistant
- Earnings date: 11/09/2020
Rubius Therapeutics, Inc. Description
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Autoimmune Disease Application Software Autoimmunity Therapies For Cancer Red Blood Cell Gout Computer Aided Engineering Phenylketonuria Pku Therapeutic Applications Cystinuria Enzyme Replacement Therapies Homocystinuria Rtx
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.71 |
| 52 Week Low | 4.2 |
| Average Volume | 2,156,938 |
| 200-Day Moving Average | 8.94 |
| 50-Day Moving Average | 17.50 |
| 20-Day Moving Average | 25.25 |
| 10-Day Moving Average | 24.75 |
| Average True Range | 3.14 |
| ADX | 50.39 |
| +DI | 33.15 |
| -DI | 11.70 |
| Chandelier Exit (Long, 3 ATRs ) | 29.29 |
| Chandelier Exit (Short, 3 ATRs ) | 24.01 |
| Upper Bollinger Band | 31.65 |
| Lower Bollinger Band | 18.85 |
| Percent B (%b) | 0.39 |
| BandWidth | 50.69 |
| MACD Line | 2.10 |
| MACD Signal Line | 2.79 |
| MACD Histogram | -0.6909 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.52 | ||||
| Resistance 3 (R3) | 25.62 | 25.19 | 25.24 | ||
| Resistance 2 (R2) | 25.19 | 24.77 | 25.13 | 25.15 | |
| Resistance 1 (R1) | 24.53 | 24.51 | 24.32 | 24.43 | 25.06 |
| Pivot Point | 24.10 | 24.10 | 23.99 | 24.04 | 24.10 |
| Support 1 (S1) | 23.44 | 23.68 | 23.23 | 23.34 | 22.70 |
| Support 2 (S2) | 23.01 | 23.42 | 22.95 | 22.61 | |
| Support 3 (S3) | 22.35 | 23.01 | 22.52 | ||
| Support 4 (S4) | 22.25 |
